SEC Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 11, 2016
    
ALEXION PHARMACEUTICALS, INC.
-----------------------------------------------------------
(Exact name of registrant as specified in its charter)

Delaware
000-27756
13-3648318
------------------
------------------
---------------
(State or other jurisdiction of
of incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)


100 College Street, New Haven, Connecticut 06510
---------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code:    (203) 272-2596
   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨
Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))






Item 5.07    Submission of Matters to a Vote of Security Holders.

Alexion Pharmaceuticals, Inc. held its Annual Meeting of Shareholders on May 11, 2016 in New Haven, Connecticut. The results of the matters voted on by the shareholders are set forth below.

1.    The election of directors:
 

Votes For
 

Votes Against
 

Abstentions
 
Broker
Non-Votes
 
 
 
 
 
 
 
 
Leonard Bell
201,874,672
 
41,769
 
1,464,988
 
6,149,057
Felix Baker
203,009,403
 
33,847
 
338,179
 
6,149,057
David R. Brennan
202,903,685
 
34,136
 
443,608
 
6,149,057
M. Michele Burns
177,919.416
 
3,513,000
 
21,949,013
 
6,149,057
Christopher J. Coughlin
201,916,565
 
242,902
 
1,221,962
 
6,149,057
David L. Hallal
202,732,525
 
104,364
 
544,540
 
6,149,057
John T. Mollen
194,551,604
 
3,645,127
 
5,184,698
 
6,149,057
R. Douglas Norby
194,400,590
 
2,390,392
 
6,590,447
 
6,149,057
Alvin S. Parven
193,503,434
 
3,636,900
 
6,241,095
 
6,149,057
Andreas Rummelt
202,843,487
 
94,883
 
443,059
 
6,149,057
Ann M. Veneman
202,716,902
 
45,020
 
619,507
 
6,149,057

2.
The non-binding advisory vote to approve the compensation paid to Alexion’s named executive officers as described in Alexion’s 2016 proxy statement:

Votes For
 

Votes Against
 

Abstentions
 

Broker Non-Votes
 
 
 
 
 
 
 
181,566,353
 
21,739,471
 
75,605
 
6,149,057

3.
Ratification of the appointment of PricewaterhouseCoopers LLP as Alexion's independent registered public accounting firm:

Votes For
 

Votes Against
 

Abstentions
 
 
 
 
 
208,553,894
 
914,497
 
62,095

4.
Shareholder proposal requesting the Board of Directors to amend Alexion's governing documents to give shareholders owning ten percent of Alexion stock the power to call a special meeting:





Votes For
 

Votes Against
 

Abstentions
 

Broker Non-Votes
 
 
 
 
 
 
 
85,527,534
 
117,762,563
 
91,332
 
6,149,057





Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 16, 2016
 
ALEXION PHARMACEUTICALS, INC.
 
 
By:    /s/ Michael V. Greco      
Name: Michael V. Greco
Title: Senior Vice President of Law and Corporate Secretary